September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Understanding mechanistic interplay between oxidative stress and the complement system in AMD pathogenesis
Author Affiliations & Notes
  • Travis L. Stiles
    Ophthalmology, Shiley Eye Institute, UC San Diego, San Diego, California, United States
  • Hongjun Du
    Ophthalmology, Xijing Hospital, Shangxi, China
  • Xu Xiao
    Sichuan Provential People‘s Hospital, Chengdu, Sichuan, China
  • Christopher Douglas
    Ophthalmology, Shiley Eye Institute, UC San Diego, San Diego, California, United States
  • Daisy Ho
    Ophthalmology, Shiley Eye Institute, UC San Diego, San Diego, California, United States
  • Peter Shaw
    Ophthalmology, Shiley Eye Institute, UC San Diego, San Diego, California, United States
  • Footnotes
    Commercial Relationships   Travis Stiles, None; Hongjun Du, None; Xu Xiao, None; Christopher Douglas, None; Daisy Ho, None; Peter Shaw, None
  • Footnotes
    Support  Funding support: This work was supported by the National Eye Institute (R01 R01 EY025693 and P30EY022589).
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5810. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Travis L. Stiles, Hongjun Du, Xu Xiao, Christopher Douglas, Daisy Ho, Peter Shaw; Understanding mechanistic interplay between oxidative stress and the complement system in AMD pathogenesis. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5810.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : AMD is a leading cause of vision loss worldwide. Homeostatic disruption of lipid handling, particularly in terms of oxidized phosholipids (oxPLs), disrupts tightly controlled inflammatory suppression and can lead to AMD pathology. Our lab previously demonstrated a putative link between risk-associated variation in complement factor H (CFH) and oxidative stress in that risk genotypes lead to decreased association with oxPLs, which results in decreased protection of RPE from accumulation of lipids and inflammation. As expression of CFHR1 is also associated with increased AMD risk, we hypothesized the conferred risk was a result of similar impaired oxPL interaction.

Methods : Binding of CFH or CFHR1 protein to native or oxLDL was assessed by ELISA. Lipid/CFH(R1) complex effect on stimulation of pro-inflammatory cytokines was assessed in ARPE-19 cells post 18 hours incubation via qPCR for inflammatory markers. For lipid accumulation studies, ARPE-19 cells were incubated with 25 µg/ml concentration of native or oxLDL (+/- CFH or CFHR1) for 48 hours. After incubation, the cells were fixed and stained with heated Oil red O/propylene glycol and lipid accumulation quantified as lipid droplets/cell per total 100 cells counted.

Results : CFHR1/oxPL association was not statistically different than CFH (CFH: 98136 RLU/ms ± 11250 v.s. CFHR1: 87643 RLU/ms ± 12054, MEAN ± SD). CFH incubation with oxLDL was able to reduce the inflammatory cytokine IL-6 (OxLDL: 2.35 ± 0.23 v.s. OxLDL/CFH: 1.43 ± 0.16, relative fold change to native LDL normalized with GAPDH). CFHR1 did not elicit the same protective benefits (OxLDL: 2.35 ± 0.23 v.s. OxLDL/CFHR1: 2.23 ± 0.29, relative fold change to native LDL normalized with GAPDH). The lipids droplets number accumulated in ARPE-19 cell were also not impacted by CFHR1 (Nat-LDL: 1.6 ± 0.5 v.s. OxLDL: 13.7 ± 1.6 v.s. OxLDL/CFH: 6.4 ± 0.7 v.s. OxLDL/CFHR1: 12.3 ± 1.4. lipids droplets/cell, Mean ± SD).

Conclusions : Contrary to our original hypothesis, CFHR1-associated risk for AMD is not due to impaired binding of oxPL molecules. However, CFHR1 interaction with oxPLs does not attenuate inflammation or lipid accumulation in RPE cells. CFHR1 is highly homologous to CFH in its included domains, but is overall smaller and lacks some of the domains contained in CFH. As a result, future studies will dissect the domains within CFH necessary for protective benefits.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×